GENB vs NUVB: Which Stock Is the Better Buy?
Generate Biomedicines, Inc. and Nuvation Bio Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GENB vs NUVB, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Generate Biomedicines, Inc. (GENB) | Nuvation Bio Inc. (NUVB) | |
|---|---|---|
| Market cap | $1.7B | $1.6B |
| Revenue (latest FY) | $31.89M | $62.90M |
| Net income (latest FY) | $-203.15M | $-204.63M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -637.0% | -325.3% |
| Return on equity | 33.0% | -66.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full GENB vs NUVB breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GENB's full financials → Open NUVB's full financials →More comparisons
Frequently asked questions
Which is bigger, GENB or NUVB?
Generate Biomedicines, Inc. is larger by market capitalization — $1.7B versus $1.6B.
Which grows faster, GENB or NUVB?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
GENB fundamentals → · NUVB fundamentals → · All 1,500+ companies → · Free screener →